Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

NeurogesX submitted a new drug application (NDA) for Qutenza for the treatment of neuropatic pain associated with PHN to the U.S. Food and Drug Administration (FDA) in October 2008. Recently, a marketing authorization application (MAA) for Qutenza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. NeurogesX is currently awaiting the European Commission's decision on the CHMP's opinion.

"Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs," presented by Christopher J. Panarites, Ph.D. of NeurogesX, identified patterns of health care utilization and costs among PHN and painful diabetic neuropathy (PDN) patients, as well as matched controls. Dr. Panarites and colleagues analyzed a large managed care claims database for the calendar years 2005 and 2006. Results indicated that total annual post-diagnosis costs for PHN and PDN patients averaged $14,535 and $40,705, respectively. In addition, PHN and PDN cases had significantly higher costs compared with matched controls for total costs, costs for outpatient/professional services and pharmacy costs (p less than or equal to 0.002 for all comparisons). Inpatient costs did not significantly differ between PHN and PDN cases and matched controls.

About Neuropathic Pain

Neuropathic pain is a type of chronic pain that results from injury to, or dysfunction of, nerves in the central or peripheral nervous systems. Peripheral neuropathic pain is an inappropriate sensation of pain that results when injured or dysfunctional nerve endings send aberrant pain signals to the brain, in the absence of harmful stimuli. It can result from viruses, in cases of PHN and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as dia
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... BONITA SPRINGS, Fla., March 4 Tigris Pharmaceuticals, ... announced that its Investigational New Drug (IND) application ... accepted by the U.S. Food and Drug Administration. ... Phase I study evaluating the safety of GGTI-2418 ...
... from Collaboration Applying forensicgem(TM) Technology to CBI,s ... of Forensic Sciences Annual Meeting -- Shows ... Yield, Simplify Workflow and Minimize Potential for ... New Zealand, and RICHMOND, Va., March 4 ...
... 2008 Key milestones, - Strong R&D investments, especially in EHT Dx21 ... - Recruitment of 311 samples achieved for EHT Dx21, ... - Expansion of the strategic collaboration with Allergan and extension, ... - Appointment of a new Management Board, - New positioning of ...
Cached Biology Technology:FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 2Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEM's DNA Extraction Technology 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
(Date:7/10/2014)... , July 3, 2014 According ... by Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, ... Commercial Security and Banking & Finance), and Geography - ... by MarketsandMarkets, the global Fingerprint Sensors Market is projected ... high CAGR of 16.8% from 2014 to 2020. ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... at the National Institute of Standards and Technology (NIST) ... refrigerant fluids with low "global warming potential" (GWP) ... many decades as well as other desirable performance ... most extensive systematic search for a new class of ...
... /PRNewswire-iReach/ -- Global Information Inc is pleased to offer ... conferences around the world. Early Bird registration prices end ... save up to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ... 11, 2013 | San Francisco, California CHI,s ...
... pioneering wildlife ecologist Aldo Leopold was a meticulous taker of ... bench at his Sauk County shack in Depression-era Wisconsin, Leopold ... with the first pre-dawn calls of the indigo bunting or ... songs he heard, when he heard them, and details such ...
Cached Biology News:New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3
... Well Plate Sterile with ... range of 384-well plates ... screening and research. These ... and are suitable for ...
Request Info...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: